Start the conversation
Some biotech penny stocks are up as much as 333.9% year to date (YTD), and we've compiled the best-performing biotech penny stocks in 2017 in the list below.
Plus, after the list, I'll show you a biotech stock that has the potential to book profits of more than 120% in the next year.
Here's the full list of biotech penny stocks. Eight of the 10 stocks have triple-digit gains...
|Rank||Company (Ticker)||Price||YTD Gains|
|10||Verastem Inc. (Nasdaq: VSTM)||$2.16||89.3%|
|9||Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM)||$0.56||90.8%|
|8||Protolix Bio Therapeutics Inc. (NYSE: PLX)||$0.91||101.1%|
|7||Zosano Pharmaceutical Corp. (Nasdaq: ZSAN)||$1.58||114.1%|
|6||Rexahn Pharmaceuticals Inc. (NYSE: RNN)||$3.29||132.6%|
|5||Bellerophon Therapeutics Inc. (Nasdaq: BLPH)||$1.35||153.8%|
|4||Cleveland BioLabs Inc. (Nasdaq: CBLI)||$3.65||157.8%|
|3||Cymbay Therapeutics Inc. (Nasdaq: CBAY)||$4.67||167.1%|
|2||Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)||$4.28||212.4%|
|1||Pulmatrix Inc. (Nasdaq: PULM)||$2.60||333.9%|
While those types of gains can be tempting, we don't recommend buying penny stocks because they are too volatile for retail investors.
And because these stocks are so volatile, these impressive gains may not last.
However, we've found a biotech stock for readers today that could double your money starting as early as Aug. 1. It's not technically a penny stock, but at $12 per share, it still has plenty of room to soar.
This company is taking a new cancer treatment to market, and getting in now ensures huge profits ahead of the drug's release. The market potential of the new drug is likely to reach billions of dollars...